What happened with RAPP today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Rapport Therapeutics’ business centers on RAP-219, its most advanced experimental medicine, particularly for drug-resistant focal onset seizures. It is also testing RAP-219 for other seizures and bipolar mania. The company has no approved products and has generated no revenue; investors have funded its operations through stock sales and convertible notes rather than customers paying for medicines.
Future product sales depend on completing development and obtaining regulatory approval in each market. Rapport cannot commercialize a drug without that approval, and sales would also depend on physicians and patients adopting it and government and commercial insurers providing adequate coverage and reimbursement. Until substantial product revenue arrives, it expects to seek funding through equity, debt or collaboration and licensing arrangements.
Nearly all its candidates originated at Janssen. Rapport holds licensed development and commercialization rights, with potential milestone payments and sales royalties owed to Janssen for its TARPγ8 products, including RAP-219. It outsources all drug manufacturing and relies on a limited set of drug-substance suppliers. Tenacia is responsible for developing and commercializing RAP-219 in China and participating in certain Greater China trials.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Xenon Pharmaceuticals Inc's Phase 3 azetukalner competes with Rapport's RAP-219 for the epilepsy treatment market; both are investigational medicines, not products already sold to patients. Watch azetukalner's epilepsy trial results for the efficacy and safety RAP-219 may have to compete against.
Praxis Precision Medicines, Inc. develops PRAX-628 for focal onset seizures, making it a clinical-stage rival to Rapport's RAP-219 rather than an established seller of medicines. PRAX-628's efficacy and safety results are the comparison to watch for Rapport's prospects in that patient group.
Biohaven Ltd.'s BHV-7000 is a clinical-stage competitor to Rapport's RAP-219 for focal onset seizures, and Biohaven has made epilepsy medicines acting on Kv7 ion channels a development priority. Watch progress in that program rather than product sales: Biohaven has not yet generated product-sales revenue.
Neuropace, Inc. sells a device that monitors brain activity and delivers stimulation—the RNS System—to treat U.S. adults with drug-resistant focal epilepsy, addressing the same patient group as Rapport's investigational RAP-219. It also licenses Rapport the RNS recordings and resulting algorithm outcomes from RAP-219 trials royalty-free, making it both a treatment rival and a source of trial data.
Supernus Pharmaceuticals, Inc. already sells epilepsy medicines Trokendi XR and Oxtellar XR and is developing SPN-817, which Rapport names as a clinical-stage rival to RAP-219 for focal onset seizures. SPN-817's clinical results are the most direct comparison for RAP-219 within Supernus's broader medicine business.
Stoke Therapeutics, Inc. and Rapport both depend on advances in epilepsy treatment, though Stoke's SCN1A-targeted therapies and Rapport's RAP-219 address different patient populations. Stoke leads development of zorevunersen with funding and shared development costs from Biogen; its clinical progress offers a view of advances elsewhere in epilepsy, not a direct test of RAP-219.
Rapport relies on licenses and patents from Johnson & Johnson's Janssen to develop its TARPγ8 medicines, and successful development and sales would trigger payments back to Janssen. For the lead-candidate product, Janssen may receive up to $76 million in development milestones and $40 million in sales milestones, plus royalties on worldwide net sales.
Fed Interest Rate Decision
For Rapport Therapeutics, the Fed’s rate decision—its choice of a benchmark interest rate—can change the interest income it earns on its cash and short-term investments, a source of other income alongside its drug-development costs.
Expected4.0%Last release4.0%
If it comes in above expectations
If the rate is above the estimate, higher rates across the economy may lift the interest Rapport earns on its cash and short-term investments, adding to other income that helps offset its development spending.
If it comes in below expectations
If the rate is below the estimate, lower rates across the economy may reduce the interest Rapport earns on its cash and short-term investments, leaving less other income to offset its development spending.
Supernus Pharmaceuticals, Inc. earningsSUPN
Supernus Pharmaceuticals’ report will show how its epilepsy-medicine business and SPN-817 are progressing, giving Rapport Therapeutics a competitive reference for the same focal-onset seizure patient group it targets with RAP-219.
Separate sales of Supernus’s marketed epilepsy medicines from updates on SPN-817’s clinical progress. Steady sales and continued development would point to commercial demand for epilepsy treatment and a rival candidate advancing alongside RAP-219; weak sales or delays would suggest less commercial evidence or less immediate competition.
Rapport Therapeutics, Inc. earningsThis company
Rapport Therapeutics has no approved medicines or product sales, so this report shows what it spends advancing RAP-219 and whether its cash use is accelerating.
Read research and development expense alongside cash used in operating activities, and note what the company says about upcoming clinical work. If spending stays controlled while programs advance, its available funds can support more development; if costs rise sharply with limited progress, cash may run down sooner and reliance on financing or partnerships may deepen.
